FDA Approves Non-Chemo Lung Cancer Treatment
-
By
August 20, 2024
-
2 min
-
1
FDA approves Johnson & Johnson's chemotherapy-free combination treatment for first-line NSCLC with EGFR mutation.
-
2
Rybrevant (amivantamab-vmjw) and lazertinib are key components.
-
3
Rybrevant combination showed increased efficacy in late-stage study.
-
4
Amivantamab-vmjw disrupts growth of EGFR and MET genes.
-
5
The combination represents a significant advancement in frontline therapy for NSCLC patients with the EGFR mutation.
-
The FDA has approved Johnson & Johnson's chemotherapy-free combination treatment, a combination of Rybrevant (amivantamab-vmjw) and lazertinib, for first-line treatment of non-small cell lung cancer (NSCLC) patients with an EGFR mutation. This approval provides a potential alternative to the current standard of care and is based on data showing the efficacy of the Rybrevant combination in increasing the time patients lived without their disease worsening compared to other treatments. The combination is aimed at slowing or stopping the spread of tumorous cells and represents a significant advancement in frontline therapy for NSCLC patients with the EGFR mutation.
-
1
FDA approves Johnson & Johnson's chemotherapy-free combination treatment for first-line NSCLC with EGFR mutation.
-
2
Rybrevant (amivantamab-vmjw) and lazertinib are key components.
-
3
Rybrevant combination showed increased efficacy in late-stage study.
-
4
Amivantamab-vmjw disrupts growth of EGFR and MET genes.
-
5
The combination represents a significant advancement in frontline therapy for NSCLC patients with the EGFR mutation.
Listen Tab content
